Compare FULT & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULT | BLLN |
|---|---|---|
| Founded | 1882 | 2016 |
| Country | United States | United States |
| Employees | 3400 | 713 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | FULT | BLLN |
|---|---|---|
| Price | $22.17 | $85.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $21.40 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.9M | 360.5K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.39 | $45.96 |
| Revenue Next Year | $5.52 | $30.11 |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.26 | $61.96 |
| 52 Week High | $22.99 | $138.70 |
| Indicator | FULT | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 67.76 | 56.31 |
| Support Level | $21.54 | $79.33 |
| Resistance Level | $22.99 | $98.48 |
| Average True Range (ATR) | 0.52 | 6.98 |
| MACD | 0.15 | 0.16 |
| Stochastic Oscillator | 90.06 | 60.08 |
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.